» R&D-based and product-driven pharmaceutical company
Innovative R&D at low cost and high efficiency
» First in class and best in class products with worldwide IP protection
» Low FTW cost
» Targeting 3.5 years from discovery to US IND
» US IND trials up to proof-of-concept
» China IND trials for 'First Class New Drug' registration, fast market entry and price protection
Growth driven by global view and strategy
» Established 50,000 sq. ft. state-of-the-art R&D center in Taiwan in 2/2002 with 91 staff in total
» Parallel in-license and internal discovery for Asian and ROW markets
» Conducted four trials under US IND authority, including multi-national trial sites
» Subsidiary in Beijing for clinical trials and registration under Chinese IND authority on two occassions
» Established a platform for US/EU companies to develop and market products in China
» Risk and reward sharing: Fujisawa, P&G Pharmaceuticals, plus other partners under discussion
» TaiGen partnership opportunities
Out-licensing opportunity in late-stage projects
» Nemonoxacin for US / EU / Japan markets
Co-development / Out-licensing opportunities in early-stage projects
» TG-0054, stem and progenitor cell mobilizer
» HCV program
In-licensing opportunities in Asian development rights
» Asian prevalent diseases
» Comprehensive IP protection
Research alliance
» Risk and reward sharing
» From lead discovery / optimization to proof-of-concept clinical trials
Please contact
Peter W. Tsao, Vice President for Global Business Development
TaiGen Biotechnology Co., Ltd.
7F, 138 Shin Ming Rd., Neihu Dist., Taipei, Taiwan 114, R.O.C.
Tel. 886-2-2790-1861, ext. 1705 (Taipei Office)
Fax. 886-2-2796-3606 (Taipei Office)
ptsao@taigenbiotech.com
Top
